Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06717347 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06717347 · ClinicalTrials.gov record · last posted 2026-08-21

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

StatusRecruiting
PhasePhase 3
Started2025-01-27
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Protocol amendment history 1 change detected by DataLookout

2026-05-16
Trial sites expanded: 253 → 256 locations
Trial Details
NCT Number NCT06717347
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 1,046 participants
Start Date 2025-01-27
Primary Completion 2029-07-02 (estimated)
Study Completion 2032-03-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-21